Why has the Avita Medical (ASX:AVH) share price just hit a 2-year low?

We look at what's behind the challenging time for the Avita Medical share price.

| More on:
a doctor's hands take the bandaged foot and lower leg of a young girl in assessing treatment.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It was a disappointing day for the Avita Medical Inc (ASX: AVH) share price as it hit a new 2-year low.

The regenerative medicine company has failed to regain momentum since the beginning of its fall from grace during the COVID-19 crash. Since its peak in February 2020, Avita Medical shares have plummeted 75% to their current position.

In the past month, there have been only two notable announcements from the skin restoration company. Let's revisit these to grasp what's influencing the company's multi-year low share price.

One step forward, two steps back

Investor sentiment towards the Avita Medical share price is clearly swaying towards the negative. However, it hasn't been all bad news for the RECELL spray-on skin system developer in recent weeks.

On 4 November, the medical technology company revealed that the US Centers for Medicare and Medicaid Services had approved Avita's application for a new category code. In short, this means patients will now be able to offset the cost associated with the company's RECELL burns treatment across hospitals and surgical centres.

Importantly, the news hinted at the possibility of widespread adoption of the company's skin regeneration treatment. In turn, the announcement captured the excitement of ASX investors. This update resulted in a ~15% spike in the Avita Medical share price.

However, the excitement was short-lived as the company's shares soured the following week. The downfall was triggered by Avita's earnings report for the first quarter of FY22.

Interestingly, the company's performance was surprisingly robust. For instance, total revenue increased 39% to $7.0 million. Meanwhile, gross profit margin improved 300 basis points to 85%. Perhaps investors had been hoping for an earnings positive quarter, while Avita delivered a loss of $5.9 million during the period.

Avita Medical share price snapshot

Despite the disappointing share price performance by Avita Medical over the last two years, on a longer timescale, it looks more positive.

From January 2019, the company's share price has gained 153%. This equates to an annual growth rate of approximately 38.8% over the near 3-year time span. For comparison, the S&P/ASX 200 Index (ASX: XJO) has an annual growth rate of ~10.2% before dividends over the same duration.

Motley Fool contributor Mitchell Lawler has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended Avita Medical Limited. The Motley Fool Australia has recommended Avita Medical Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Broker says this ASX 200 biotech stock is a top buy

Let's see what Bell Potter is saying about this biotech.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why CSL shares are a buy today despite the looming Trump tariffs

A leading expert believes CSL shares are still trading for a bargain today. Here's why.

Read more »

A businesswoman pulls her glasses down in shock to look at the bad news on her computer.
Healthcare Shares

Why did the Telix share price just crash 16%?

Investors are sending the Telix share price plunging today. But why?

Read more »

Broker analysing the share price.
Healthcare Shares

Expert: 2 ASX healthcare stocks to avoid before reporting season

Not all healthcare stocks are created equal.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Should I buy Pro Medicus or CSL shares ahead of earnings season?

The ASX healthcare sector may be currently undervalued.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Why Mesoblast shares can keep storming higher

More big returns could be on the way for buyers of this high risk stock according to Bell Potter.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

The Mesoblast share price just rocketed 38%! Here's why

ASX investors just sent the Mesoblast share price up 38%. But why?

Read more »

couple having a happy discussion with a banker
Healthcare Shares

Expert: 4 ASX healthcare stocks to buy ahead of reporting season

Could these ASX healthcare stocks be good additions to your portfolio?

Read more »